Moreover, tumor patients with EGFR amplification demonstrated worse prognosis compared with patients without EGFR amplification (P < 0.0001) (Figure 1B), suggesting that EGFR amplification was a biomarker correlated with the clinical outcomes across different tumor types. Here, EGFR is linked to neoplasm.